|
🐜
|
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
33 auth.
Jianxing He,
C. Su,
W. Liang,
Shidong Xu,
Lin Wu,
Xiangning Fu,
Xiaodong Zhang,
D. Ge,
Qun Chen,
W. Mao,
Lin Xu,
Chun Chen,
Bing Hu,
G. Shao,
Jian Hu,
...
Jian Zhao,
Xiaoqing Liu,
Zhidong Liu,
Zheng Wang,
Ze-min Xiao,
Taiqian Gong,
Wen-zhao Lin,
Xingya Li,
F. Ye,
Yang Liu,
Haitao Ma,
Yunchao Huang,
Jianying Zhou,
Zhonglin Wang,
Junke Fu,
L. Ding,
L. Mao,
Caicun Zhou
|
6 |
2021 |
6
🐜
|
|
🐢
|
lncRNA ITGB8-AS1 functions as a ceRNA to promote colorectal cancer growth and migration through integrin-mediated focal adhesion signaling
13 auth.
Xiaoting Lin,
Shiwen Zhuang,
Xue Chen,
Jun Du,
Longhua Zhong,
Jiancheng Ding,
Lei Wang,
Jia Yi,
Guo-Sheng Hu,
Guo-hui Tang,
...
Xi Luo,
Wen Liu,
F. Ye
|
6 |
2021 |
6
🐢
|
|
🐢
|
Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis
Xin Zhao,
Linlin Chen,
Jingxun Wu,
J. You,
Q. Hong,
F. Ye
|
4 |
2021 |
4
🐢
|
|
🐜
|
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
12 auth.
Qiao Li,
Jiaxuan Liu,
Qingyuan Zhang,
Q. Ouyang,
Yang Zhang,
Qiang Liu,
...
T. Sun,
F. Ye,
Baochun Zhang,
S. Xia,
Bangyong Zhang,
Binghe Xu
|
4 |
2024 |
4
🐜
|
|
🐜
|
CircPVT1 promotes ER‐positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS
11 auth.
Jia Yi,
Lei Wang,
Guo-Sheng Hu,
Yue-ying Zhang,
Jiao Du,
Jiancheng Ding,
...
Xiang Ji,
H. Shen,
Hai-hua Huang,
F. Ye,
Wen Liu
|
4 |
2023 |
4
🐜
|
|
🐜
|
Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer.
8 auth.
Xianwu Wang,
Xi Luo,
Yunpeng Tian,
Ting Wu,
Jian Weng,
Zhu Li,
...
F. Ye,
Xuefei Huang
|
4 |
2021 |
4
🐜
|
|
🐜
|
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
76 auth.
Yuankai Shi,
K. Lei,
Yuming Jia,
Bingqiang Ni,
Zhiyong He,
M. Bi,
Xicheng Wang,
Jianhua Shi,
Ming Zhou,
Qiang Sun,
Guolei Wang,
Dongji Chen,
Y. Shu,
Lianke Liu,
Zhongliang Guo,
...
Yong Liu,
Junquan Yang,
Ke Wang,
Ke Xiao,
Lin Wu,
T. Yi,
Debin Sun,
Ma-fei Kang,
Tianjiang Ma,
Y. Mao,
Jinsheng Shi,
T. Tang,
Yan Wang,
P. Xing,
D. Lv,
W. Liao,
Zhiguo Luo,
Bin Wang,
Xiaohong Wu,
Xiao-Li Zhu,
Shuhua Han,
Q. Guo,
Rongyu Liu,
Zhiwei Lu,
Jianyong Zhang,
J. Fang,
Changlu Hu,
Yinghua Ji,
Guolong Liu,
Hong Lu,
Dedong Wu,
Junhong Zhang,
Shuyang Zhu,
Zheng Liu,
W. Qiu,
F. Ye,
Yan Yu,
Yanqiu Zhao,
Q. Zheng,
Jun Chen,
Z. Pan,
Yiping Zhang,
Wen-fei Lian,
B. Jiang,
B. Qiu,
Guojun Zhang,
Hua Zhang,
Yanju Chen,
Yuan Chen,
H. Duan,
Manxiang Li,
Shengming Liu,
Lijun Ma,
H. Pan,
Xia Yuan,
Xu Yuan,
Yulong Zheng,
E. Gao,
Li Zhao,
Shumin Wang,
Can Wu
|
4 |
2021 |
4
🐜
|
|
🐜
|
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
35 auth.
Jin Li,
S. Qin,
L. Wen,
Junsheng Wang,
W. Deng,
Weijian Guo,
T. Jia,
D. Jiang,
Guifang Zhang,
Yifu He,
Y. Ba,
H. Zhong,
Lin Wang,
Xiaoyan Lin,
Jianwei Yang,
...
Jun Zhao,
Y. Bai,
Xiang-yuan Wu,
F. Gao,
Guogui Sun,
Yong-feng Wu,
F. Ye,
Qiong Wang,
Z. Xie,
T. Yi,
Yong Huang,
Guohua Yu,
Lin Lu,
Ying Yuan,
Wei Li,
Likun Liu,
Yuping Sun,
Ying Sun,
L. Yin,
Z. Hou
|
3 |
2023 |
3
🐜
|
